NASDAQ:AVIR Atea Pharmaceuticals Q1 2025 Earnings Results & Report $4.63 -0.35 (-7.03%) Closing price 04:00 PM EasternExtended Trading$4.64 +0.00 (+0.11%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Atea Pharmaceuticals beat analyst earnings expectations in its Q1 2025 results, released May 12, 2025. The company reported EPS of -$0.40 versus the -$0.56 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 12, 2025TimeAfter Market ClosesConference Call4:00 PM ET Atea Pharmaceuticals EPS ResultsActual EPS-$0.40Consensus EPS -$0.56Beat/MissBeat by +$0.16One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAtea Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAtea Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Atea Pharmaceuticals Q1 2025 Earnings FAQ Did Atea Pharmaceuticals beat earnings estimates for Q1 2025? Atea Pharmaceuticals (NASDAQ:AVIR) reported earnings of -$0.40 per share for Q1 2025, beating the consensus estimate of -$0.56. The report was announced on Monday, May 12, 2025. When is Atea Pharmaceuticals' next earnings date? Atea Pharmaceuticals' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Atea Pharmaceuticals on the company's earnings history page. Atea Pharmaceuticals Earnings HeadlinesAtea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comAtea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceSeptember 8, 2026 | globenewswire.comElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.October 14 at 1:00 AM | Behind the Markets (Ad)Atea (AVIR) Q2 2026 Earnings Call TranscriptAugust 19, 2026 | finance.yahoo.comAtea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13, 2026 | finance.yahoo.comAtea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call TranscriptAugust 12, 2026 | seekingalpha.comSee More Atea Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atea Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atea Pharmaceuticals and other key companies, straight to your email. Email Address About Atea PharmaceuticalsAtea Pharmaceuticals (NASDAQ:AVIR) is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral infections. The company’s research centers on small-molecule therapies designed to interfere with viral replication, with the goal of addressing diseases for which convenient and effective oral treatment options are needed. Atea’s lead investigational product is bemnifosbuvir, an oral nucleotide polymerase inhibitor developed for the treatment of COVID-19. The company has also pursued antiviral candidates for other infectious diseases, including hepatitis C and dengue. Atea previously entered into a collaboration with Roche to develop bemnifosbuvir for COVID-19, but the collaboration ended in 2022, returning development rights to Atea. Founded in 2012 and headquartered in Boston, Massachusetts, Atea conducts its research and development activities primarily in the United States. As a clinical-stage company, its products remain subject to clinical testing and regulatory review and are not necessarily approved or commercially available in all targeted markets.View Atea Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
